AbCellera Biologics (ABCL) Current Deferred Revenue (2020 - 2026)

AbCellera Biologics' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 76.2% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (down 76.2% YoY) and the FY2025 annual result came in at $13.5 million, down 29.63% from the prior year.
• Current Deferred Revenue was $7.7 million for Q1 2026 at AbCellera Biologics, down from $13.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $37.2 million in Q1 2023 and bottomed at $7.7 million in Q1 2026.
• A 5-year average of $23.9 million and a median of $21.5 million in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue surged 89.88% — and 2026, when it tumbled 76.2%.
• AbCellera Biologics' Current Deferred Revenue stood at $14.3 million in 2022, then soared by 89.88% to $27.2 million in 2023, then decreased by 29.21% to $19.2 million in 2024, then slipped by 29.63% to $13.5 million in 2025, then slumped by 42.75% to $7.7 million in 2026.
• Business Quant data shows ABCL's Current Deferred Revenue at $7.7 million in Q1 2026, $13.5 million in Q4 2025, and $21.5 million in Q3 2025.